Jiangsu Aidea Pharmaceutical Group Co., Ltd. (SHA:688488)
China · Delayed Price · Currency is CNY 17.50
+0.74 (4.42%)
Feb 13, 2026, 3:00 PM CST
SHA:688488 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Operating Revenue | 669.07 | 415.54 | 409.06 | 242.86 | 254.97 | 287.41 |
Other Revenue | 2.26 | 2.26 | 2.3 | 1.36 | 0.74 | 1.65 |
| 671.33 | 417.8 | 411.36 | 244.22 | 255.71 | 289.06 | |
Revenue Growth (YoY) | 64.27% | 1.57% | 68.44% | -4.49% | -11.54% | -16.27% |
Cost of Revenue | 272.84 | 224.53 | 245.01 | 172.18 | 181.33 | 145.22 |
Gross Profit | 398.48 | 193.28 | 166.36 | 72.04 | 74.38 | 143.84 |
Selling, General & Admin | 356.2 | 251.95 | 199.69 | 167.57 | 88.24 | 81.73 |
Research & Development | 90.87 | 89.89 | 63.18 | 63.91 | 47.67 | 26.32 |
Other Operating Expenses | 13.58 | 5.61 | 5.95 | 3.33 | 3.31 | 3.68 |
Operating Expenses | 461.42 | 344.85 | 272.56 | 243.68 | 136.73 | 110.07 |
Operating Income | -62.94 | -151.58 | -106.2 | -171.64 | -62.34 | 33.77 |
Interest Expense | -16.15 | -15.36 | -11.76 | -3.92 | -0.25 | -2.94 |
Interest & Investment Income | 2.01 | 9.49 | 14.1 | 9.67 | 10.47 | 3.56 |
Currency Exchange Gain (Loss) | 0.02 | 0.02 | -0.1 | 0.88 | -0.2 | -0.37 |
Other Non Operating Income (Expenses) | -0.81 | -0.13 | -0.08 | -0.11 | -0.09 | -0.05 |
EBT Excluding Unusual Items | -77.87 | -157.56 | -104.04 | -165.11 | -52.41 | 33.96 |
Impairment of Goodwill | -0.63 | -0.63 | - | - | - | - |
Gain (Loss) on Sale of Investments | -4.6 | 10.76 | 1.54 | 7.19 | 0.31 | 1.31 |
Gain (Loss) on Sale of Assets | -0.39 | -0.47 | -0.06 | -0.28 | 1.58 | - |
Asset Writedown | 12.39 | -28.33 | - | - | - | -0.1 |
Other Unusual Items | 10.23 | 10.23 | 10.47 | 15.82 | 8.25 | 12.01 |
Pretax Income | -60.87 | -166 | -92.09 | -142.38 | -42.27 | 47.18 |
Income Tax Expense | 0.12 | -27.16 | -16.02 | -18.29 | -12.29 | 7.41 |
Earnings From Continuing Operations | -61 | -138.84 | -76.07 | -124.09 | -29.99 | 39.77 |
Minority Interest in Earnings | -26.1 | -2.37 | - | - | - | - |
Net Income | -87.1 | -141.2 | -76.07 | -124.09 | -29.99 | 39.77 |
Net Income to Common | -87.1 | -141.2 | -76.07 | -124.09 | -29.99 | 39.77 |
Net Income Growth | - | - | - | - | - | 18.20% |
Shares Outstanding (Basic) | 351 | 421 | 423 | 414 | 428 | 398 |
Shares Outstanding (Diluted) | 351 | 421 | 423 | 414 | 428 | 398 |
Shares Change (YoY) | -21.13% | -0.44% | 2.17% | -3.44% | 7.71% | 6.38% |
EPS (Basic) | -0.25 | -0.34 | -0.18 | -0.30 | -0.07 | 0.10 |
EPS (Diluted) | -0.25 | -0.34 | -0.18 | -0.30 | -0.07 | 0.10 |
EPS Growth | - | - | - | - | - | 11.11% |
Free Cash Flow | -23.89 | -82.06 | -237.43 | -232.85 | -107.15 | 13.74 |
Free Cash Flow Per Share | -0.07 | -0.20 | -0.56 | -0.56 | -0.25 | 0.04 |
Dividend Per Share | - | - | - | - | - | 0.048 |
Gross Margin | 59.36% | 46.26% | 40.44% | 29.50% | 29.09% | 49.76% |
Operating Margin | -9.38% | -36.28% | -25.82% | -70.28% | -24.38% | 11.68% |
Profit Margin | -12.97% | -33.80% | -18.49% | -50.81% | -11.73% | 13.76% |
Free Cash Flow Margin | -3.56% | -19.64% | -57.72% | -95.34% | -41.90% | 4.75% |
EBITDA | -11.34 | -104.12 | -64.27 | -138.39 | -35.09 | 55.4 |
EBITDA Margin | -1.69% | -24.92% | -15.62% | -56.66% | -13.72% | 19.16% |
D&A For EBITDA | 51.59 | 47.45 | 41.93 | 33.26 | 27.25 | 21.63 |
EBIT | -62.94 | -151.58 | -106.2 | -171.64 | -62.34 | 33.77 |
EBIT Margin | -9.38% | -36.28% | -25.82% | -70.28% | -24.38% | 11.68% |
Effective Tax Rate | - | - | - | - | - | 15.71% |
Revenue as Reported | 671.33 | 417.8 | 411.36 | 244.22 | 255.71 | 289.06 |
Advertising Expenses | - | - | - | 2.69 | 1.56 | 0.68 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.